Hervana Bio
Non-hormonal Female Contraceptive Technology Offering Protection Against STIs
Company Overview
Snapshot
Founded in June 2008 by Rachel Teitelbaum, PhD, Hervana Bio operates with 1–10 employees. The company has secured $1.1 million in total capital across two funding rounds. In December 2012, Hervana Bio received a grant from the Bill & Melinda Gates Foundation.
Business overview
Hervana Bio is a biopharmaceutical company focused on developing women's health products. The company's core technology is a non-hormonal female contraceptive platform designed to offer protection against sexually transmitted infections. Its lead product, LJ-102, aims to provide an effective, long-lasting contraceptive solution without the drawbacks of hormone-based methods, targeting markets where current options are contraindicated or undesirable. Hervana Bio operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals and Drugs Discovery & Development.
Strategic signal
In April 2024, Hervana Bio was highlighted by CTech for its development of a new non-hormonal contraceptive, marking the first such innovation in 60 years. This signals significant progress in addressing a critical unmet need in women's health and positions the company as a potential disruptor in the pharmaceutical and femtech markets, attracting investor attention to its clinical trial stage product.
Log in to access full profile ›Company Intelligence Q&A
- What is Hervana Bio's primary focus?
- Hervana Bio is a biopharmaceutical company dedicated to developing women's health products, particularly focusing on non-hormonal female contraceptive technology that also offers protection against sexually transmitted infections.
- When was Hervana Bio founded and by whom?
- Hervana Bio was founded in June 2008 by Rachel Teitelbaum, PhD.
- What significant grant did Hervana Bio receive?
- In December 2012, Hervana Bio received a grant from the Bill & Melinda Gates Foundation for its contraceptive development efforts.
- What is the status of Hervana Bio's product development?
- Hervana Bio's lead product, LJ-102, is currently in the clinical trial stage, aiming to provide a highly effective, long-lasting, and hormone-free contraceptive.
- What was a recent notable mention for Hervana Bio?
- In April 2024, CTech featured Hervana Bio for developing what is described as the first new, non-hormonal contraceptive in 60 years.